KH 1060 + infliximab

KH 1060 + infliximab is a combination of two agents with distinct mechanisms of action.

• KH 1060 (lexacalcitol) is a highly potent synthetic vitamin D3 analogue (over 100 times more active than calcitriol) that modulates cell proliferation and differentiation. It has demonstrated potential in treating diseases characterized by accelerated cell growth and T lymphocyte activation such as psoriasis and possibly certain cancers. Its mechanism involves binding to the vitamin D receptor to regulate gene expression related to immune modulation and cellular growth.
• Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-alpha), a key cytokine in inflammatory processes. By binding TNF-alpha, it neutralizes its activity and reduces inflammation associated with autoimmune diseases like Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and severe plaque psoriasis.

The rationale for combining these drugs would be to leverage the immunomodulatory effects of both agents—one through vitamin D receptor-mediated pathways affecting T cells and keratinocytes (KH 1060), the other through direct inhibition of TNF-alpha-driven inflammation (infliximab). However, there are no published clinical studies or regulatory approvals specifically for this combination.